Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Subscribe To Our Newsletter & Stay Updated
